In this file photo taken on June 23, 2020 The logo of the biopharmaceutical company CureVac is seen in front of the company's headquarters in Tuebingen, southern Germany on June 23, 2020. / AFP / THOMAS KIENZLE
BRUSSELS: The European Commission said on Thursday it had concluded exploratory talks with CureVac regarding the purchase of 225 million doses of the German biotech firm's potential COVID-19 vaccine.
"Today we concluded talks with the European company CureVac to increase the chances of finding an effective coronavirus vaccine," EU Health Commissioner Stella Kyriakides said.
The EU will now begin talks on a contract with CureVac aimed at securing the supply of its potential vaccine for all 27 EU member states should the shot prove safe and effective against COVID-19.
